Stock With Great Potential
Analyst says this stock could make quick strides with its unbelievable assets.
Learn more

PHIO Insider Trading (Phio Pharmaceuticals)

Insider Ownership Percentage: 0.30%
Insider Buying (Last 12 Months): $9,780.00
Insider Selling (Last 12 Months): $0.00

Phio Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Phio Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Phio Pharmaceuticals Share Price & Price History

Current Price: $0.69
Price Change: Price Increase of +0.04 (6.13%)
As of 05/19/2022 05:00 PM ET

This chart shows the closing price history over time for PHIO up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Last Century's Oil Boom Repeats Today With Lithium?
The budding lithium industry looks similar to early days of the oil boom. In fact, lithium has been called the "new oil." As internal combustion engines give way to lithium-filled electric vehicle batteries, demand for the metal is skyrocketing. The U.S. is desperate for more domestic sources of lithium, and geologists are pointing to Nevada.
See Why Nevada Lithium Opportunity Looks Promising

Phio Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/16/2021Gerrit DispersynCEOBuy6,000$1.63$9,780.00View SEC Filing Icon  
3/3/2021Gerrit DispersynCEOBuy2,500$3.03$7,575.00View SEC Filing Icon  
3/3/2021Robert L. FerraraDirectorBuy682$3.15$2,148.30View SEC Filing Icon  
8/19/2020Gerrit DispersynCEOBuy2,000$2.50$5,000.00View SEC Filing Icon  
See Full Table
Warning: The Last Value Play Gone After August?
In this market...There's ONE STOCK (priced at just under $2) that could be $20 and STILL be a bargain. It brought in more income – including equity sales - in the last 12 months than Disney, Square or Tesla.

But a key announcement in August could send this stock rocketing skyward
Get the Details Now.

SEC Filings (Institutional Ownership Changes) for Phio Pharmaceuticals (NASDAQ:PHIO)

13.15% of Phio Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PHIO by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Phio Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/13/2022Renaissance Technologies LLC41,500$37K0.0%+310.9%0.304%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.304,119$0.27M0.0%+6.8%2.226%Search for SEC Filing on Google Icon
5/13/2022Cetera Investment Advisers90,000$80K0.0%+125.0%0.659%Search for SEC Filing on Google Icon
2/15/2022Millennium Management LLC45,397$45K0.0%-63.0%0.335%Search for SEC Filing on Google Icon
11/16/2021Cetera Investment Advisers30,000$61K0.0%N/A0.222%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Advisers LP153,100$0.31M0.0%+165.8%1.131%Search for SEC Filing on Google Icon
11/16/2021Millennium Management LLC122,693$0.25M0.0%+1,122.7%0.907%Search for SEC Filing on Google Icon
11/12/2021Geode Capital Management LLC107,192$0.22M0.0%+22.5%0.792%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.35,592$72K0.0%-17.8%0.263%Search for SEC Filing on Google Icon
9/17/2021Virtu Financial LLC27,110$61K0.0%+74.7%0.200%Search for SEC Filing on Google Icon
8/16/2021Goldman Sachs Group Inc.19,002$43K0.0%N/A0.140%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.276,561$0.63M0.0%+125.4%2.043%Search for SEC Filing on Google Icon
8/12/2021Dimensional Fund Advisors LP23,960$54K0.0%-31.2%0.177%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC15,522$42K0.0%N/A0.115%Search for SEC Filing on Google Icon
5/14/2021Dimensional Fund Advisors LP34,808$93K0.0%+38.3%0.257%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC87,501$0.23M0.0%+330.6%0.647%Search for SEC Filing on Google Icon
5/10/2021GSA Capital Partners LLP132,333$0.36M0.1%+30.5%0.978%Search for SEC Filing on Google Icon
3/26/2021Susquehanna International Group LLP12,058$32K0.0%N/A0.085%Search for SEC Filing on Google Icon
3/8/2021Dimensional Fund Advisors LP25,177$68K0.0%N/A0.178%Search for SEC Filing on Google Icon
2/25/2021Dimensional Fund Advisors LP25,177$68K0.0%N/A0.178%Search for SEC Filing on Google Icon
2/4/2021GSA Capital Partners LLP101,401$0.27M0.0%+376.6%1.754%Search for SEC Filing on Google Icon
12/11/2020Virtu Financial LLC35,929$77K0.0%N/A0.622%Search for SEC Filing on Google Icon
11/6/2020GSA Capital Partners LLP21,278$46K0.0%N/A0.368%Search for SEC Filing on Google Icon
7/16/2020Wedbush Securities Inc.33,374$73K0.0%N/A0.577%Search for SEC Filing on Google Icon
5/15/2020Sabby Management LLC255,194$0.45M0.2%N/A8.901%Search for SEC Filing on Google Icon
5/12/2020JPMorgan Chase & Co.21,681$38K0.0%N/A0.755%Search for SEC Filing on Google Icon
2/14/2020UBS Group AG45,409$0.43M0.0%+43.3%6.997%Search for SEC Filing on Google Icon
2/13/2020Renaissance Technologies LLC333,890$57K0.0%+585.9%51.447%Search for SEC Filing on Google Icon
1/28/2020SG Americas Securities LLC792,374$0.14M0.0%+12.3%121.904%Search for SEC Filing on Google Icon
11/4/2019SG Americas Securities LLC705,353$0.19M0.0%+16.9%2.756%Search for SEC Filing on Google Icon
8/16/2019CVI Holdings LLC406,358$0.15M0.1%-32.8%1.701%Search for SEC Filing on Google Icon
8/14/2019Citadel Advisors LLC85,621$33K0.0%+148.9%0.358%Search for SEC Filing on Google Icon
6/30/2019SG Americas Securities LLC603,528$0.23M0.0%+163.8%2.526%Search for SEC Filing on Google Icon
4/29/2019SG Americas Securities LLC228,825$0.10M0.0%+39.8%1.026%Search for SEC Filing on Google Icon
4/12/2019Virtu Financial LLC238,544$0.11M0.0%N/A1.070%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Phio Pharmaceuticals logo
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Read More on Phio Pharmaceuticals

Today's Range

Now: $0.69
Low: $0.65
High: $0.71

50 Day Range

MA: $0.97
Low: $0.66
High: $2.35

52 Week Range

Now: $0.69
Low: $0.62
High: $2.47

Volume

253,601 shs

Average Volume

759,851 shs

Market Capitalization

$9.45 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Who are the company insiders with the largest holdings of Phio Pharmaceuticals?

Phio Pharmaceuticals' top insider shareholders include:
  1. Gerrit Dispersyn (CEO)
  2. Robert L Ferrara (Director)
Learn More about top insider investors at Phio Pharmaceuticals.

Who are the major institutional investors of Phio Pharmaceuticals?

Phio Pharmaceuticals' top institutional investors include:
  1. Vanguard Group Inc. — 2.23%
  2. Cetera Investment Advisers — 0.66%
  3. Renaissance Technologies LLC — 0.30%
  4. Concourse Financial Group Securities Inc. — 0.00%
Learn More about top institutional investors of Phio Pharmaceuticals stock.

Which institutional investors are buying Phio Pharmaceuticals stock?

During the previous quarter, PHIO stock was purchased by institutional investors including:
  1. Cetera Investment Advisers
  2. Renaissance Technologies LLC
  3. Vanguard Group Inc.
During the previous year, these company insiders have bought Phio Pharmaceuticals stock:
  1. Gerrit Dispersyn (CEO)
  2. Robert L Ferrara (Director)
Learn More investors buying Phio Pharmaceuticals stock.
The Secret to Financial Freedom (True Financial Independence!)
Mark your calendar now...Thursday, June 9, at 8 p.m. ET.

That's when Bill O'Reilly will press stock-picking legend Alexander Green to reveal - for the first time ever - the secret to obtaining truly life-changing wealth in America.

You're Invited to Join FREE - Discover the Secret to True Financial Independence!
>>>